The Consequences of Reinfection with M. tuberculosis

结核分枝杆菌再感染的后果

基本信息

  • 批准号:
    9096704
  • 负责人:
  • 金额:
    $ 76.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2019-12-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Vaccines against many infectious diseases are effective because prior infection with the pathogen also induces sterilizing immunity. In contrast, there are numerous reports in the literature of disease caused by reinfection with Mycobacterium tuberculosis in those who have previously had tuberculosis, and in fact, prior tuberculosis increases the risk of subsequent disease, either through relapse or reinfection. In addition, mixed infections in tuberculosis patients have also been reported. However, seminal epidemiologic studies suggested that people with clinically latent M. tuberculosis infection can protect against development of tuberculosis due to reinfection. A review of the literature reveals that the effects of prior M. tuberculosis infection on subsequent infection are poorly studied and not well understood. In this application, we undertake a detailed study of the consequences of reinfection with M. tuberculosis. We bring together cutting edge technology for analysis of bacterial populations and immune responses in individual granulomas in an established non-human primate model of tuberculosis to address how a primary infection influences a secondary infection. We hypothesize that primary infection and the ensuing immune response will impair progression of the secondary infection at the granuloma level. We will dissect the immune responses in primary and secondary lesions to identify those factors that mediate killing of bacteria in the lesions. Finally, we will investigate clinically relevant scenarios of reinfection: challenge with a heterologous lineage of M. tuberculosis and treatment of M. tuberculosis infection prior to reinfection. The studies here will uncover basic and novel aspects of tuberculosis biology and immunology, as well as provide key translational insights into vaccine development and the consequences of treating latent infections in humans.
 描述(由申请方提供):针对许多传染病的疫苗是有效的,因为先前感染病原体也会诱导灭菌免疫。与此相反, 在文献中有许多关于在先前患有结核病的人中由结核分枝杆菌再感染引起的疾病的报道,事实上,先前的结核病通过复发或再感染增加了随后疾病的风险。此外,还报告了结核病患者的混合感染。然而,精液流行病学研究表明,临床潜伏M。结核病感染可以防止由于再感染而发展为结核病。文献回顾表明,先验M。结核病感染对后续感染的影响研究甚少,也没有很好地了解。在本申请中,我们进行了详细的研究与M的再感染的后果。结核我们汇集了尖端技术,用于在已建立的非人灵长类结核病模型中分析单个肉芽肿中的细菌种群和免疫反应,以解决原发性感染如何影响继发性感染。我们假设原发感染和随后的免疫反应将损害肉芽肿水平继发感染的进展。我们将剖析原发性和继发性病变中的免疫反应,以确定介导杀死病变中细菌的因素。最后,我们将研究临床相关的再感染情况: 用M的异源谱系攻击。结核病及M.结核病在再次感染之前。这些研究将揭示结核病生物学和免疫学的基本和新方面,并为疫苗开发和治疗人类潜伏感染的后果提供关键的翻译见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SARAH FORTUNE其他文献

SARAH FORTUNE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SARAH FORTUNE', 18)}}的其他基金

Establishing the Genetic Basis of Altered Drug Responses in Mycobacterium tuberculosis
建立结核分枝杆菌药物反应改变的遗传基础
  • 批准号:
    10595538
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
Establishing the Genetic Basis of Altered Drug Responses in Mycobacterium tuberculosis
建立结核分枝杆菌药物反应改变的遗传基础
  • 批准号:
    10390301
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制
  • 批准号:
    10027082
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制
  • 批准号:
    10925119
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制
  • 批准号:
    10252739
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制
  • 批准号:
    10691842
  • 财政年份:
    2019
  • 资助金额:
    $ 76.54万
  • 项目类别:
Bacterial Determinants of Tuberculosis Susceptibiliy
结核病易感性的细菌决定因素
  • 批准号:
    10219088
  • 财政年份:
    2017
  • 资助金额:
    $ 76.54万
  • 项目类别:
PE and PPE Function
PE 和 PPE 功能
  • 批准号:
    7258173
  • 财政年份:
    2007
  • 资助金额:
    $ 76.54万
  • 项目类别:
PE and PPE Function
PE 和 PPE 功能
  • 批准号:
    7500066
  • 财政年份:
    2007
  • 资助金额:
    $ 76.54万
  • 项目类别:
Variation in M. tuberculosis in response to host selection
结核分枝杆菌对宿主选择的反应发生变化
  • 批准号:
    7426989
  • 财政年份:
    2007
  • 资助金额:
    $ 76.54万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.54万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了